Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?
Recruitment status was Not yet recruiting
Aspirin (ASA) has been shown, in an animal model, to attenuate the ototoxic properties of cisplatin. The researchers plan to investigate this in patients undergoing cisplatin chemotherapy.
The researchers hypothesise that low-dose aspirin can prevent cisplatin induced ototoxicity in the clinical setting.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?|
- hearing loss [ Time Frame: before and after chemotherapy ] [ Designated as safety issue: No ]
- hearing loss and tinnitus questionnaires [ Time Frame: before and after cisplatin treatment ] [ Designated as safety issue: No ]
|Study Start Date:||February 2008|
|Estimated Study Completion Date:||February 2010|
Placebo Comparator: 2
placebo OD during course of chemotherapy
OD for course of cisplatin chemotherapy
325mg ASA OD during course of chemotherapy
325mg ASA OD for the duration of the cisplatin
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00578760
|Contact: Emma Barker, FRCS, PhD||001-416-946-4501 ext email@example.com|
|Princess Margaret Hospital||Not yet recruiting|
|Toronto, Ontario, Canada|
|Sub-Investigator: Emma Barker, FRCS, PhD|